Multiple Myeloma | Recurrent disease Post Transplantation | Multiple Myeloma High risk
Item
mm in frank relapse after a single or tandem transplant or high risk myeloma
boolean
C0026764 (UMLS CUI [1])
C0277556 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0040732 (UMLS CUI [2,3])
C0026764 (UMLS CUI [3,1])
C0332167 (UMLS CUI [3,2])
Transplantation
Item
patients with prior transplant must be more than 4 months after the last transplant
boolean
C0040732 (UMLS CUI [1])
Karnofsky Performance Status | Karnofsky Performance Status Due to Bone pain caused by Multiple Myeloma
Item
karnofsky performance score >or =70, or a performance score of 50-70 exclusively due to bone pain caused by myeloma
boolean
C0206065 (UMLS CUI [1])
C0206065 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0151825 (UMLS CUI [2,3])
C0015127 (UMLS CUI [2,4])
C0026764 (UMLS CUI [2,5])
Age
Item
18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Continuance of life Expected
Item
an expected survival greater than 3 months
boolean
C0038952 (UMLS CUI [1,1])
C1517001 (UMLS CUI [1,2])
Absolute neutrophil count | Platelet Count measurement
Item
anc >1,000/microliters, platelet count > 100,000/microliters
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
Informed Consent | Informed Consent Donor
Item
donor and patient must have signed an irb-approved consent and been informed about the investigational nature of the study
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0040288 (UMLS CUI [2,2])
Donor HIV Serology negative
Item
donor must have negative serology for hiv
boolean
C0040288 (UMLS CUI [1,1])
C0019682 (UMLS CUI [1,2])
C0919674 (UMLS CUI [1,3])
Donor Relative Haploidentical | Donor Appropriate Leukapheresis | Donor Mismatch KIR Ligand Patient Graft vs Host Reaction
Item
available haplo-identical family donor fit to undergo leukapheresis and mismatched for kir-ligand(s) with the patient in the graft-versus host direction.
boolean
C0040288 (UMLS CUI [1,1])
C0080103 (UMLS CUI [1,2])
C3829897 (UMLS CUI [1,3])
C0040288 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C0023416 (UMLS CUI [2,3])
C0040288 (UMLS CUI [3,1])
C1881865 (UMLS CUI [3,2])
C3642144 (UMLS CUI [3,3])
C0030705 (UMLS CUI [3,4])
C0018134 (UMLS CUI [3,5])
Cell storage CD34+ cell Autografting
Item
stored cells for autografting of at least 30 million cd34+ cells/kg
boolean
C2025607 (UMLS CUI [1,1])
C0882849 (UMLS CUI [1,2])
C0040736 (UMLS CUI [1,3])
Cell storage CD34+ cell Engraft failure
Item
back-up cells of at least 20 million cd34+ cells/kg in case of non-engraftment.
boolean
C2025607 (UMLS CUI [1,1])
C0882849 (UMLS CUI [1,2])
C2242642 (UMLS CUI [1,3])
Disease Response | M Protein In Urine | Urine light chain measurement | Serum Free Immunoglobulin Light Chain
Item
there must be an unambiguous marker for response to therapy in the first ten patients. therefore the patient must have detectable and quantifiable m-protein or light chain excretion in urine, light chain quantification in serum (freelite) or clear radiological signal lesion(s) in order to be eligible
boolean
C1704632 (UMLS CUI [1])
C0700271 (UMLS CUI [2,1])
C0042037 (UMLS CUI [2,2])
C1445962 (UMLS CUI [3])
C2827352 (UMLS CUI [4])
Recurrent disease | Toxic effect Acceptable | Multiple Myeloma High risk | Cytogenetic abnormalities | Metaphase Abnormal
Item
after 10 relapsed patients have been treated and toxicity is deemed acceptable, high-risk myeloma (defined as the presence of abnormal cytogenetics or metaphase analysis) patients without relapse can be entered
boolean
C0277556 (UMLS CUI [1])
C0600688 (UMLS CUI [2,1])
C1879533 (UMLS CUI [2,2])
C0026764 (UMLS CUI [3,1])
C0332167 (UMLS CUI [3,2])
C0008625 (UMLS CUI [4])
C1621812 (UMLS CUI [5,1])
C0205161 (UMLS CUI [5,2])
Intravenous chemotherapy Affecting T-Lymphocyte | antibody therapy Intravenous Affecting T-Lymphocyte | Intravenous chemotherapy Affecting Natural Killer Cells | antibody therapy Intravenous Affecting Natural Killer Cells | Cyclophosphamide | Melphalan | Anti-Thymocyte Globulin | Campath 1H | fludarabine
Item
intravenous chemotherapy or antibody therapy affecting t-lymphocytes and/or natural killer cells e.g. cyclophosphamide, melphalan, atg, campath-1h etc. within the past 2 weeks prior to commencement of conditioning. last therapy is less than 14 days prior to starting fludarabine
boolean
C0413365 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0039194 (UMLS CUI [1,3])
C0281176 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C0392760 (UMLS CUI [2,3])
C0039194 (UMLS CUI [2,4])
C0413365 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C0022688 (UMLS CUI [3,3])
C0281176 (UMLS CUI [4,1])
C1522726 (UMLS CUI [4,2])
C0392760 (UMLS CUI [4,3])
C0022688 (UMLS CUI [4,4])
C0010583 (UMLS CUI [5])
C0025241 (UMLS CUI [6])
C0003442 (UMLS CUI [7])
C1178562 (UMLS CUI [8])
C0059985 (UMLS CUI [9])
Fever | Communicable Disease Requirement Intravenous antibiotic therapy
Item
fever or active infection, requiring iv antibiotics
boolean
C0015967 (UMLS CUI [1])
C0009450 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0559680 (UMLS CUI [2,3])
Liver function | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
liver function: total bilirubin > 2xuln or ast/alt >3xuln
boolean
C0232741 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
Renal function | Dialysis procedure
Item
renal function: patients on dialysis
boolean
C0232804 (UMLS CUI [1])
C0011946 (UMLS CUI [2])